Literature DB >> 27779754

Connections between constitutional mismatch repair deficiency syndrome and neurofibromatosis type 1.

K Wimmer1, T Rosenbaum2, L Messiaen3.   

Abstract

Constitutional mismatch repair (MMR) deficiency (CMMRD) is a rare childhood cancer susceptibility syndrome resulting from biallelic germline loss-of-function mutations in one of the MMR genes. Individuals with CMMRD have high risk to develop a broad spectrum of malignancies and frequently display features reminiscent of neurofibromatosis type 1 (NF1). Evaluation of the clinical findings of genetically proven CMMRD patients shows that not only multiple café-au-lait macules but also any of the diagnostic features of NF1 may be present in a CMMRD patient. This phenotypic overlap may lead to misdiagnosis of CMMRD patients as having NF1, which impedes adequate management of the patients and their families. The spectrum of CMMRD-associated childhood malignancies includes high-grade glioma, acute myeloid leukaemia or rhabdomyosarcoma, also reported as associated with NF1. Reported associations between NF1 and these malignancies are to a large extent based on studies that neither proved the presence of an NF1 germline mutation nor ruled-out CMMRD in the affected. Hence, these associations are challenged by our current knowledge of the phenotypic overlap between NF1 and CMMRD and should be re-evaluated in future studies. Recent advances in the diagnostics of CMMRD should render it possible to definitely state or refute this diagnosis in these individuals.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  acute myeloid leukaemia; café-au-lait spot; childhood cancer; constitutional mismatch repair deficiency; germline mutation; high-grade glioma; mismatch repair gene; neurofibromatosis type 1; rhabdomyosarcoma

Mesh:

Year:  2017        PMID: 27779754     DOI: 10.1111/cge.12904

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  29 in total

Review 1.  An update on the central nervous system manifestations of neurofibromatosis type 1.

Authors:  J Stephen Nix; Jaishri Blakeley; Fausto J Rodriguez
Journal:  Acta Neuropathol       Date:  2019-04-08       Impact factor: 17.088

2.  Neuroimaging Findings in Children with Constitutional Mismatch Repair Deficiency Syndrome.

Authors:  A Kerpel; M Yalon; M Soudack; J Chiang; A Gajjar; K E Nichols; Z Patay; S Shrot; C Hoffmann
Journal:  AJNR Am J Neuroradiol       Date:  2020-04-30       Impact factor: 3.825

3.  Genetic basis of neurofibromatosis type 1 and related conditions, including mosaicism.

Authors:  Eric Legius; Hilde Brems
Journal:  Childs Nerv Syst       Date:  2020-06-29       Impact factor: 1.475

4.  Diagnostic challenges in a child with early onset desmoplastic medulloblastoma and homozygous variants in MSH2 and MSH6.

Authors:  Julia Taeubner; Katharina Wimmer; Martine Muleris; Olivier Lascols; Chrystelle Colas; Christine Fauth; Triantafyllia Brozou; Joerg Felsberg; Jasmin Riemer; Michael Gombert; Sebastian Ginzel; Jessica I Hoell; Arndt Borkhardt; Michaela Kuhlen
Journal:  Eur J Hum Genet       Date:  2018-01-04       Impact factor: 4.246

5.  Reply.

Authors:  N Kadom; R C Castellino; D S Wolf
Journal:  AJNR Am J Neuroradiol       Date:  2019-05-09       Impact factor: 3.825

Review 6.  [Pigmented macules as possible early signs of genetic syndromes].

Authors:  H Hamm; K Emmerich; J Olk
Journal:  Hautarzt       Date:  2019-07       Impact factor: 0.751

7.  Patients with High-Grade Gliomas and Café-au-Lait Macules: Is Neurofibromatosis Type 1 the Only Diagnosis?

Authors:  L Guerrini-Rousseau; M Suerink; J Grill; E Legius; K Wimmer; L Brugières
Journal:  AJNR Am J Neuroradiol       Date:  2019-05-09       Impact factor: 3.825

8.  Cellular vaccination of MLH1-/- mice - an immunotherapeutic proof of concept study.

Authors:  Claudia Maletzki; Yvonne Saara Gladbach; Mohamed Hamed; Georg Fuellen; Marie-Luise Semmler; Jan Stenzel; Michael Linnebacher
Journal:  Oncoimmunology       Date:  2017-12-14       Impact factor: 8.110

Review 9.  Review: Ewing Sarcoma Predisposition.

Authors:  Pablo Gargallo; Yania Yáñez; Antonio Juan; Vanessa Segura; Julia Balaguer; Bárbara Torres; Silves Oltra; Victoria Castel; Adela Cañete
Journal:  Pathol Oncol Res       Date:  2019-10-26       Impact factor: 3.201

10.  Combined Gemcitabine and Immune-Checkpoint Inhibition Conquers Anti-PD-L1 Resistance in Low-Immunogenic Mismatch Repair-Deficient Tumors.

Authors:  Inken Salewski; Julia Henne; Leonie Engster; Bjoern Schneider; Heiko Lemcke; Anna Skorska; Peggy Berlin; Larissa Henze; Christian Junghanss; Claudia Maletzki
Journal:  Int J Mol Sci       Date:  2021-06-01       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.